Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neovasc Inc. NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter... see more

Recent & Breaking News (NDAQ:NVCN)

Neovasc Announces First Quarter 2019 Financial Results

PR Newswire May 9, 2019

Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer(TM)

Canada NewsWire May 6, 2019

Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

Canada NewsWire May 3, 2019

Neovasc Provides Highlights from Annual Conference of the DGK, the German Society of Cardiology; Symposium Generates Growing Support for Reducer

Canada NewsWire April 26, 2019

Neovasc Announces Resolution of Last Remaining Active Litigation

Canada NewsWire April 17, 2019

Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer(TM) Improves Diastolic Function in patients suffering from severe angina

Canada NewsWire April 17, 2019

Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

Canada NewsWire March 21, 2019

Neovasc Wins German Court Appeal; Announces German Court's Decision to Dismiss CardiAQ's Claim to Co-inventorship of a European Patent for Tiara™

Canada NewsWire March 21, 2019

Reducer Featured in Presentation at American College of Cardiology's Annual Meeting

Canada NewsWire March 19, 2019

Neovasc Announces Closing of $5 Million Public Offering of Common Shares

Canada NewsWire March 15, 2019

Neovasc Completes Successful Quality System Surveillance Audit

Canada NewsWire March 14, 2019

Neovasc to Announce Year Ended December 31, 2018 Financial Results on Thursday, March 21

PR Newswire March 13, 2019

The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

Benzinga.com  March 13, 2019

Neovasc Announces Pricing of $5 Million Public Offering of Common Shares

Canada NewsWire March 13, 2019

Neovasc Announces Proposed Public Offering of Common Shares

Canada NewsWire March 12, 2019

Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares

Canada NewsWire March 12, 2019

Neovasc Announces Reducer™ Implant "Live Case" at the CRT Meeting in Washington, DC

Canada NewsWire March 5, 2019

Neovasc's Tiara™ Mitral Valve Replacement Technology Featured in Update Presentation at the CRT 2019 Meeting

Canada NewsWire March 4, 2019

Neovasc announces closing of $5 million public offering of common shares

Canada NewsWire February 28, 2019

Neovasc to Present Corporate Overview at the 8th Annual SVB Leerink Global Healthcare Conference

Canada NewsWire February 27, 2019